We identified 36 high-frequent shared putative neoantigens derived from eight oncogenic driver mutations with more than 1% coverage of multiple cancer patients in the 9079 TCGA cohort (Table S1), e.g. HLA-A*03:01_KIGDFGLATEK from BRAF_p.V600E with 5.60% (508/9079) in Pan-Cancer. This evidence concerns the gene BRAF and cancer.